Quelltext anzeigen

{{up|PHA antivirals by mechanism}}
----
drug: darunavir
comb: cobicistat
----
{{tp|p=32325127|t=2020. Darunavir does not prevent SARS-CoV-2 infection in HIV patients |pdf=|usr=}}
{{tp|p=32479865|t=2020. Lack of antiviral activity of darunavir against SARS-CoV-2.|pdf=|usr=008}}
{{tp|p=32671131|t=2020. Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19.|pdf=|usr=014}}
{{tp|p=32676695|t=2020. Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection.|pdf=|usr=014}}
{{tp|p=32856282|t=2020. Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6.|pdf=|usr=018}}
{{tp|p=32882767|t=2020. Use of Darunavir-Cobicistat as a Treatment Option for Critically Ill Patients with SARS-CoV-2 Infection.|pdf=|usr=019}}
{{tp|p=33221868|t=2020. Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection.|pdf=|usr=021}}
{{tp|p=C7337805|t=?. Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19.|pdf=|usr=015}}
{{tp|p=32292805|t=2020. Data on the stability of darunavir/cobicistat suspension after tablet manipulation.|pdf=|usr=011}}
{{tp|p=31676833|t=2019. The HIV protease inhibitor darunavir prevents kidney injury via HIV-independent mechanisms.|pdf=|usr=}}
{{tp|p=32855991|t=2020. Reply to: "Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19".|pdf=|usr=018}}
{{ttp|p=32297571|t=2020. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus|pdf=|usr=}}